The Ministry of Health and Prevention, MoHAP, in partnership with Abbott, has revealed the success of implanting the highly precise device “CardioMEMS PA sensor” for patients with heart failure.
The announcement comes as part of MoHAP’s participation in the Arab Health 2020, Dubai, which lasts until January 30.
The new device reduces hospital admissions by 58%, as it can predict the health condition of the patient's heart and send an email to his doctor if there are indications of heart failure, thus taking the necessary treatment measures.
The CardioMEMS ™ HF system features a wireless sensor that is implanted in the pulmonary artery (PA) to directly measure PA pressure of patients with advanced heart failure.
The CardioMEMS HF System allows patients to transmit critical information about their heart failure status to a clinician on a regular basis, without the need for additional clinic or hospital visits. This provides clinicians with the ability to detect worsening heart failure sooner and adjust treatment to reduce the likelihood that the patient will need to be hospitalized.
Predictive Treatment Solutions
The device is measuring the percentage of fluid trapped in the pulmonary artery causing heart failure and it doesn’t require batteries or replaceable parts. Once implanted, it measures the PA pressure precisely and continuously.
This helps detect symptoms in earlier stages and contributes to faster treatment, in addition to reducing the rate of hospitalization and the death rate due to heart failure.
HE Dr. Youssif Al Serkal, Assistant Undersecretary for the Ministry’s Hospitals Sector, said: “The UAE is the world’s first in implementing this innovative technology with the aim of providing continuous smart medical solutions through the wearable technology and predictive data analysis, as part of the UAE Strategy for the Fourth Industrial Revolution. This would help support more future medical decisions and proactive follow-up of the patient's condition remotely, as well as preventive health care.”
It also contributes to supporting MoHAP’s plans to improve the national indicator of the number of cardiovascular deaths, according to the objectives of the national agenda for the UAE Vision 2021, he concluded.
Improving the National Indicator of Cardiovascular Disease Deaths
Dr. Kalthoum Al Baloushi, Director of MoHAP’s Hospitals Administration, said: “This innovative technology would help improve the quality of services provided for patients and reinforce the access to these reduced-cost services. The new technology allows clinicians and nursing staff to easily monitor the patient’s status through wireless communication. The doctor can resort to the information sent by the PA sensor to make changes to the treatment plan before feeling symptoms.”
“With the aim of promoting a supportive environment for cardiovascular health in schools, MoHAP has several national cardiovascular disease programs and initiatives including early screening program for critical congenital heart anomalies "CCHD" for newborns in hospitals using artificial intelligence techniques, and "Safe Hearts" program that targets primary school students to provide early detection services for congenital heart disease,” she concluded.
-Ends-
© Press Release 2020Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
